Locations:
Search IconSearch
July 6, 2017/Cancer

How Are You Achieving Reductions in Time to Treat for Colorectal, Breast and GI Cancers?

The short answer from Chairman Conor Delaney, MD, PhD

15-DDI-2421-Delaney-650×450-CQD

Q: Time to treat is on the rise nationally ― and it’s associated with worsened survival, according to a recent study presented at ASCO. How have you achieved reductions in time to treat for colorectal, breast and GI cancers and what efforts are ongoing?

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

A: Time to treat for cancer patients is a huge focus for us at the Digestive Disease & Surgery Institute.

While there is surprisingly little evidence showing that a longer time to treat makes cancer outcomes worse, we are all concerned that any unnecessary wait can only be a bad thing. Perhaps more important, any wait is obviously very distressing for a patient who has recently been diagnosed with a condition that’s stressful for them, their family and their friends.

We’re putting a lot of effort into time to treat at Cleveland Clinic. We are optimizing physicians’ schedules and providing them with the proper support so we can give our patients better access to our care. For many services, we also have weekly or more frequent “huddles,” in which physicians, nurses and our navigation team members come together to get patients in with the right physician or surgeon. The goal? To find where patients best fit into the schedule, allowing them the quickest access to the most suitable and personalized treatment.

In addition, we have multidisciplinary tumor boards for all of the cancers that we treat at Cleveland Clinic. Every cancer patient has his or her case discussed by a team of physicians, surgeons, oncologists, radiologists and radiation oncologists who come up with an individualized treatment plan.

These tumor boards allows us to track the date of diagnosis and actively manage the patient’s pathway through any necessary investigations or testing before treatment is initiated. It also ensures our whole team is on the same page about coordinating treatment.

Advertisement

The result? A patient-centered system that individualizes and perfects the right treatment pathway for each patient ― all while moving the patient through the pathway of testing and treatment as expediently as possible.

— Conor Delaney, MD, PhD

Chairman, Digestive Disease & Surgery Institute Cleveland Clinic

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad